Global Expansion and Competition in the Weight-Loss Drug Market
The weight-loss drug market is rapidly expanding globally, with a shift from injections to pills and intense competition between pharmaceutical giants like Novo Nordisk and Eli Lilly. Regulatory scrutiny is also impacting new product offerings in this lucrative sector.
7 Feb, 23:19 — 15 Feb, 12:00
How outlets covered this
Coverage (2 sources)
Weight-loss race: how switch from injections to pills is expanding big pharma’s hopes
Tablets could make treatment more mainstream, with sector predicted to be worth $200bn by end of the decade “I just felt slow: I want to be able to do anything my kids want to do and not have weight be a factor. Even a ride or a water park – things have weight limits,” says Melody Ewert, 44, from Minnesota. Ewert has just switched from Eli Lilly’s Zepbound weekly injection to Novo Nordisk’s new daily Wegovy pill. Analysts believe the arrival of easy-to-take tablets could push weight-loss treatments further into the mainstream in a year that has been described as “pivotal” for the booming anti-obesity market. The new pills, like the jabs, mimic the gut hormone GLP-1 that regulates appetite. Continue reading...
By Julia Kollewe
Read at source →Hims & Hers Withdraws Knockoff Weight-Loss Pill After Regulatory Scrutiny
Federal officials had warned that the new product from the online provider of weight loss drugs might be illegal.
By Rebecca Robbins
Read at source →